Navigation Links
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
Date:9/10/2007

SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the development of a novel and proprietary orally-administered compound, SB1518, for the treatment of myeloproliferative disorders (MPD) and certain hematological malignancies. MPD is believed to be caused by a specific mutation (V617F) of JAK2 and is a closely related group of hematological malignancies in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is a privately-held biotech company focusing on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer.

SB1518 is a small molecule JAK2-selective kinase inhibitor. It has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the activating V617F mutation which is found in high frequencies among three types of MPD and in some leukemias. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of MPD and other diseases.

"SB1518 has demonstrated excellent anti-proliferative and anti-tumor activity, combined with very good tolerability in relevant in vitro and in vivo models. SB1518 will address an important unmet medical need due to the lack of specific and effective long-term medical treatment for patients with MPD," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "This promising new compound is our second success in the last twelve months and represents an important step in building S*BIO's strong pipeline of proprietary, targeted anti-cancer compounds."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor which is currently in Phase 1 clinical trials. S*BIO's target-driven approach to innovative small molecule
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
7. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
(Date:11/24/2014)... 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ... President and CEO of Inovio Pharmaceuticals, will be joined by ... the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, at ... listing on the Nasdaq Global Select Market.  ... "We are honored to ring the Nasdaq Opening Bell on ...
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3
... Oct. 30 Novo Nordisk Inc. announced the re-launch ... campaign through a rebranded Web site and a ... many daily challenges, and Novo Nordisk is committed to ... lifetime of possibilities. , These new online resources were ...
... 30 NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... today announced it will hold a conference call on Friday, ... to report results for its third quarter 2009. , ... and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer. ...
Cached Medicine Technology:Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results 2NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results 3
(Date:11/24/2014)... November 24, 2014 Abington Health ... MD has joined The Neurology Group and has ... Sclerosis Center. , A graduate of Vinnica Medical ... at Albert Einstein Medical Center in Philadelphia and completed ... Multiple Sclerosis Center at Weill Cornell Medical College. Ternopolska ...
(Date:11/24/2014)... 2014 The Holiday Inn Westbury - ... and Children's Association to donate various items consisting ... and other such items.The Association's program is aimed toward ... living in nursing homes, assisted living facilities and nursing ... well being of seniors throughout the Long Island area. ...
(Date:11/24/2014)... Philadelphia, PA (PRWEB) November 24, 2014 ... care coordination and disease management services to health ... to implement Essette’s Medical Management software suite. ... SaaS platform in a program to reduce patients' ... includes Population Health Management, Care Management, Utilization Management, ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 iFitDress.com, a well-known ... long black evening gowns . They are now offered ... special offer will last from now to Dec. 15. The ... market. , All the company’s high quality items are ideal ... spending a large sum of money. All its new mint ...
(Date:11/23/2014)... York, NY (PRWEB) November 23, 2014 ... that allege heart attacks, strokes, deep vein thrombosis ... filed in a federal multidistrict litigation (MDL) underway ... LLP reports. , Court documents updated on ... Multidistrict Litigation (JPML) show the filing of 259 ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... birth control in all the schools of England in a ... ,There are currently 2,409 nurses who work in primary and ... a massive extension, reported the online edition of Daily Mail. ... funded to have at least one full-time qualified nurse working ...
... European Breast Cancer Conference (EBCC-5) have called that patients should ... in the field. Doctors and patient groups said that women ... like Herceptin that could help prolong their survival and well ... and radiation therapy are available to women in the United ...
... of Veterinary Medicine have established a national surveillance ... humans and animals using medical records of pets. ... of Epidemiology. Larry Glickman of the School of ... Hospital, a nationwide chain of veterinary hospitals to ...
... without any warning has become a health hazard today with ... per annum. Internal automatic defibrillators (IAD) have now come to ... these apparatus have brought many back from the brink of ... that approximately 1000 people die each year due to sudden ...
... crisis has its origin in HIV/AIDS, weak health systems and ... die from TB every year, 1.5 million are Africans. ... Research Foundation (AMREF) clinic in the Kenyan slum, revealed that ... infected with HIV. According to Nzioka, about two thirds of ...
... a study by the New England Research Institutes in collaboration ... much or too little// are at a greater risk of ... is based on studies done on over 1709 men, in ... over a period of 15 yrs. ,According to ...
Cached Medicine News:Health News:Pets As Disease Watchdogs 2Health News:Seconds Between Life And Death 2
... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Fluorometholone ophthalmic suspension USP, 0.1% is a topical anti-inflammatory agent for ophthalmic use....
... tool that allows to see the fundus ... stimulated. Besides it also includes the refractive ... between the pupil picture and the fundus ... is especially suited for animal research and ...
Medicine Products: